Metabolism and effects on platelet function of 6 g/d for 6 d of either eicosapentaenoic acid (EPA, C20:5w-3) or docosahexaenoic acid (DCHA, C22:6w-3) in volunteers were compared in a randomized crossover study. Incorporation kinetics revealed that EPA appeared in plasma free fatty acids and plasma phospholipids after 4 h, but was not incorporated into platelet phosphatidylcholine and -ethanolamine until day 6. This indicates that platelet fatty acid composition does not immediately reflect that of the surrounding plasma milieu, but rather may be determined during megakaryocyte maturation. Importantly, EPA was not incorporated into platelet phosphatidylinositol or -serine in vivo, thus reflecting selective biosynthesis of platelet phospholipids. After dietary EPA, C22:5w-3 increased in plasma and platelet phospholipids. In contrast, DCHA-levels were unaltered. After DCHA-ingestion, C20:5w-3 concentrations rose in plasma phospholipids, implying that retroconversion took place. These findings indicate that dietary DCHA can serve as a source of EPA. During this short-term study, ingestion of both EPA and DCHA resulted in reduced platelet aggregation in response to collagen. The response to ADP was lowered significantly only by DCHA. After either EPA or DCHA, thromboxane formation was unchanged in serum derived from clotted whole blood as was total in vivo synthesis measured by excretion of immunoreactive 2,3-dinor thromboxane B2/3. We conclude that DCHA reduces platelet responsiveness, contributing to the antithrombotic effects of w-3 fatty acid-rich fish oil ingestion, of which DCHA is a major component.
Introduction
Fish and fish oils, rich in the two w-3 fatty acids, eicosapentaenoic (EPA)' and docosahexaenoic acid (DCHA) Receivedfor publication 8 August 1985.
1. Abbreviations used in this paper: DCHA, C22:6w-3, docosahexaenoic acid; EPA, C20:5w-3, eicosapentaenoic acid; TX, thromboxane.
investigation in animals, volunteers, and patients. Their antithrombotic and antiinflammatory properties imply prophylactic and therapeutic potential (1) (2) (3) (4) (5) (6) . In humans, eicosanoids from EPA are less thrombogenic and less proinflammatory than those derived from arachidonic acid (7) (8) (9) (10) . Additional benefits may be attributable to the plasma lipid-lowering action ofdietary fish oils and fractions derived therefrom (3, [11] [12] [13] [14] . We recently carried out a detailed metabolic study of time and dose relationships of long-term dietary cod liver oil supplementation (15) . These reports involved the use of fish and fish oils, i.e., mixtures of fatty acids, of which both EPA and DCHA are major constituents. It is not known whether DCHA exerts antithrombotic effects of its own during intake of mixtures containing w-3 fatty acids. Therefore, we performed a randomized crossover study designed to compare individual metabolic and functional effects of the purified w-3 fatty acids, EPA, and DCHA in male volunteers. It will be shown that dietary DCHA can be retroconverted to EPA in humans. Interestingly, DCHA by itself reduces platelet responsiveness, and contributes therefore to the antithrombotic properties of fish and fish oils. Moreover, the results indicate that platelet phospholipid fatty acid composition may be determined during cell maturation.
Methods
Study protocol. Seven healthy male volunteers, 29-38 yr of age, weight 58-82 kg, were recruited from hospital staff. Informed consent was obtained. The volunteers were advised to take vitamin E (100 mg/d), refrain from all drug intake, and to exclude dietary fish for I wk before and during the study periods. After an overnight fast, venipuncture was performed with minimal venous stasis on an antecubital vein with 19-gauge butterfly sets before and after the 6-day intake of either 6 g EPA or DCHA ethylester. 24-h urine samples were obtained at these time points. Four volunteers were randomized to receive EPA initially, and after a 10-wk interval the DCHA regimen was administered. One volunteer was unable to participate in his second (DCHA) phase ofthe study for personal reasons. In a randomized subset of four volunteers, blood was drawn for determination of fatty acid composition of plasma, phospholipids in plasma, and platelet phospholipid subclasses, before, 4 (1 5, 16 ).
Methods. Fatty acid analyses in plasma and of phospholipids in plasma and platelets were performed as described (15) . Platelet phos- p0.001 in adjusted platelet-rich plasma (250,000/41) in an aggregometer in response to 0.50 Ag/ml collagen and 1.0 mM ADP (15) . Thromboxane (TX)B2,3 in whole clotted blood (I h, 370C) and urinary 2,3-dinor TXB2,3 were determined radioimmunologically (15) . The paired t test was applied.
Results
Fatty acid alterations. Supplementation of the diet with either EPA or DCHA for 6 d induced significant qualitative and quantitative changes in plasma free fatty acids and in phospholipids of plasma and platelets ( Figs. 1 and 2 ). Despite significant increases in plasma levels of EPA, platelet EPA remained constant over a 24-h period (Fig. 1) . Ingested EPA was not incorporated into platelet phosphatidylinositol or -serine at any time (detection limit of EPA was 1% relative to arachidonate). This confirms and extends our previous study with fish oil (16). In the subsequent 5 d, levels of 20:5w-3 almost tripled in plasma phospholipids as well as in platelet phosphatidylcholine and -ethanolamine ( Fig. 1) .
During dietary EPA, 22:5w-3 changed minimally in the first 24 h, but this was followed by a significant rise in all compartments, whereas 22:6w-3 remained at control values (Fig. 1) .
DCHA ingestion resulted in a doubling of control levels in both plasma and platelet phospholipids. However, this was accompanied by an unanticipated increase in 20:5w-3 in plasma phospholipids, which could only have resulted from retroconversion of DCHA (Fig. 2) . With regard to 22:5w-3, a small but significant decrease in plasma and platelet phospholipids was noted during DCHA ingestion (Fig. 2) .
Significant changes ofany other fatty acid were only observed during EPA supplementation. Arachidonic acid decreased in plasma free fatty acids, whereas linoleic acid decreased in both plasma and platelet phospholipids (data not shown).
Platelet aggregation. As shown in Fig. 3 (left (Fig. 3, right) . The excretion rate of urinary immunoreactive 2,3-dinor TXB2/3 was unaltered in volunteers with normal basal excretion rates, but it decreased in the one volunteer with high control excretion rates after both EPA and DCHA.
Safety. All volunteers were repeatedly questioned concerning side effects, and no side effects were reported. Laboratory studies of blood, urine, and chemistries were unremarkable during the study.
Discussion
In this study we compared the metabolism and effects on platelet aggregation of the two major w-3 fatty acids in fish oil, EPA and DCHA individually. The major findings are: (a) retroconversion of dietary DCHA to EPA took place; (b) platelet responsiveness was reduced by DCHA, a major component of fish and fish oils; (c) platelet phospholipid fatty acid composition may be defined during cell maturation.
Fatty acid metabolism. The unexpected increase of 20:5w-3 in plasma phospholipids of volunteers ingesting 22:6w-3 represents a retroconversion phenomenon. This has only been reported previously in the rat and in vitro (17, 18) . Thus, DCHA may serve as a "reservoir" for EPA via partial j3-oxidation (19) and saturation of the resulting trans-double bond (17) .
In this study, dietary EPA was not metabolized to DCHA, which is consistent with a previous report (20) . The significance of the small quantity of 22:5w-3 observed after dietary EPA remains to be determined (21) . EPA actually accumulated in plasma free fatty acids and even more so in plasma phospholipids (Fig. 1) . In contrast, dietary supplementation with dihomo-ylinolenic acid (C20:3w-6), found in evening primrose oil, does not lead to 20:3w-6 accumulation, in that it is rapidly desaturated to arachidonic acid (3). Thus EPA, but not C20:3w-6, is metabolically available over a period of time as an eicosanoid precursor after dietary intake. 24 h after EPA ingestion, its content in platelet phosphati- dylethanolamine and -choline was substantially unchanged. In contrast, at this time point, EPA had already increased fivefold in plasma free fatty acids and doubled in plasma phospholipids (Fig. 1) . Interestingly, 6 d of EPA ingestion was required before an increase in EPA content of platelet phosphatidylethanolamine and -choline was observed. These results extend our previous conclusions (15) (26) , and 7-and 14-hydroxy-DCHA, the major in vitro metabolites (26) (27) (28) , are only found in traces ex vivo (26) . Therefore, interference with platelet function by hydroxy-DCHA seems unlikely. Thus, the mechanism by which DCHA reduces platelet aggregation responsiveness ex vivo remains to be clarified.
In this 6-d study, 6 g daily of purified dietary EPA reduced the ex vivo platelet response to collagen but not to ADP (Fig.  3) . This observation was reported in another study after 2 wk ofpurified dietary EPA (3.6 g/day, Reference 20). An additional 2 wk of EPA resulted in further inhibition of platelet responsiveness, including that to ADP (20). We conclude that dietary DCHA reduces platelet responsiveness more efficiently than EPA does. Thus, inhibition of platelet function, observed upon ingestion ofdietary fish and fish oils containing both EPA and DCHA (2-4, 15, 23) , is attributable in part to DCHA.
Thromboxane formation was measured in serum from clotted whole blood, in which ex vivo platelet stimulation was presumed to be maximal. In this short-term study, neither EPA nor DCHA affected immunoreactive TXB2/3 formation in the test system (Fig. 3) . We previously reported that, after long-term w-3 fatty acid ingestion, there was a reduction of TXB2 and immunoreactive TXB2/3 as measured by this test (15) . Thus, duration of supplementation may be important for eicosanoid production upon maximal stimulation, in that, e.g., ionophorestimulated leukotriene B4 production decreased after 6 wk, but was unchanged after 3-4 wk of w-3 fatty acid supplementation (9, 10) . Consistent with our previous report utilizing long-term dietary fish oil supplementation (15), normal excretion rates of urinary 2,3 dinor-TXB2/3 were unaltered, whereas elevated excretion rates were reduced in this short-term study. This may be attributed to reduction ofincreased in vivo platelet activation by ingestion of both EPA and DCHA.
In summary, we have demonstrated, for the first time, retroconversion of dietary DCHA to EPA in humans. DCHA ingestion resulted in a greater reduction of platelet aggregation than EPA ingestion. Thus, DCOA is an important factor in the antithrombotic effects of fish oil rich in w-3 fatty acids. In addition, our results indicate that platelet fatty acid composition does not immediately reflect that of the plasma milieu, but may be defined during cell maturation.
